No Material Deterioration in Financial Condition; Financial Statements. All consolidated financial statements for Borrower and its Subsidiaries, delivered to Collateral Agent pursuant to Sections 6.2(a)(i) and 6.2(a)(ii) fairly present in all material respects the consolidated financial condition of Borrower and its Subsidiaries, and the consolidated results of operations of Borrower and its Subsidiaries as of the dates and for the periods covered by such financial statements. There has not been any material deterioration in the consolidated financial condition of Borrower and its Subsidiaries since the date of the most recent financial statements submitted to any Lender, except as contemplated by the Annual Projections.
Appears in 3 contracts
Sources: Loan and Security Agreement (Relypsa Inc), Loan and Security Agreement (Relypsa Inc), Loan and Security Agreement (Relypsa Inc)
No Material Deterioration in Financial Condition; Financial Statements. All consolidated financial statements for Borrower and its Subsidiaries, delivered to Collateral Agent pursuant to Sections 6.2(a)(i) and 6.2(a)(ii) fairly present present, in conformity with GAAP, in all material respects respects, the consolidated financial condition of Borrower and its Subsidiaries, and the consolidated results of operations of Borrower and its Subsidiaries (subject to year-end adjustments and the absence of footnotes) as of the dates and for the periods covered by such financial statementspresented. There has not been any material deterioration in the consolidated financial condition of Borrower and its Subsidiaries since the date of the most recent financial statements submitted to any Lender, except as contemplated by the Annual Projections.
Appears in 3 contracts
Sources: Loan and Security Agreement (Syros Pharmaceuticals, Inc.), Loan and Security Agreement (Syros Pharmaceuticals, Inc.), Loan and Security Agreement (Syros Pharmaceuticals, Inc.)
No Material Deterioration in Financial Condition; Financial Statements. All consolidated financial statements for Borrower and its Subsidiaries, delivered to Collateral Agent pursuant to Sections 6.2(a)(i) and 6.2(a)(ii) fairly present present, in conformity with GAAP, in all material respects the consolidated financial condition of Borrower and its Subsidiaries, and the consolidated results of operations of Borrower and its Subsidiaries as of the dates (except with respect to unaudited financial statements, subject to normal year-end adjustments and for the periods covered by such financial statementsabsence of footnotes). There has not been any material deterioration in the consolidated financial condition of Borrower and its Subsidiaries since the date of the most recent financial statements submitted to any Lender, except as contemplated by the Annual Projections.
Appears in 3 contracts
Sources: Loan and Security Agreement (Castle Biosciences Inc), Loan and Security Agreement (Castle Biosciences Inc), Loan and Security Agreement (Castle Biosciences Inc)
No Material Deterioration in Financial Condition; Financial Statements. All consolidated financial statements for Borrower and its Subsidiaries, delivered to Collateral Agent pursuant fairly present, in conformity with GAAP (except, with respect to Sections 6.2(a)(i) and 6.2(a)(ii) fairly present unaudited financials, for the absence of footnotes), in all material respects the consolidated financial condition of Borrower and its Subsidiaries, and the consolidated results of operations of Borrower and its Subsidiaries as of the dates and for the periods covered by such financial statementsSubsidiaries. There has not been any material deterioration in the consolidated financial condition of Borrower and its Subsidiaries since the date of the most recent financial statements submitted to any Lender, except as contemplated by the Annual Projections.
Appears in 2 contracts
Sources: Loan and Security Agreement (Tocagen Inc), Loan and Security Agreement (Tocagen Inc)
No Material Deterioration in Financial Condition; Financial Statements. All consolidated financial statements for Borrower and its Subsidiaries, delivered to Collateral Agent pursuant fairly present, in conformity with GAAP (subject to Sections 6.2(a)(i) year-end adjustments and 6.2(a)(ii) fairly present the absence of footnotes with respect to interim financial statements), in all material respects the consolidated financial condition of Borrower and its Subsidiaries, and the consolidated results of operations of Borrower and its Subsidiaries as of the dates and for the periods covered by such financial statementsSubsidiaries. There has not been any material deterioration in the consolidated financial condition of Borrower and its Subsidiaries since the date of the most recent financial statements submitted to any Lender, except as contemplated by the Annual Projections.
Appears in 2 contracts
Sources: Loan and Security Agreement (Tobira Therapeutics, Inc.), Loan and Security Agreement (Tobira Therapeutics, Inc.)
No Material Deterioration in Financial Condition; Financial Statements. All consolidated financial statements for Borrower and its Subsidiaries, delivered to Collateral Agent fairly present, in conformity with GAAP, subject to normal year-end adjustments and footnotes in the case of financial statements delivered pursuant to Sections Section 6.2(a)(i) and 6.2(a)(ii) fairly present ), in all material respects the consolidated financial condition of Borrower and its Subsidiaries, and the consolidated results of operations of Borrower and its Subsidiaries as of the dates and for the periods covered by such financial statementsSubsidiaries. There has not been any material deterioration in the consolidated financial condition of Borrower and its Subsidiaries since the date of the most recent financial statements submitted to any Lender, except as contemplated by the Annual Projections.
Appears in 2 contracts
Sources: Loan and Security Agreement (Sientra, Inc.), Loan and Security Agreement (Sientra, Inc.)